Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Findings of Research Misconduct.

Federal register·2026
Same journal

Findings of Research Misconduct.

Federal register·2026
Same journal

Findings of Research Misconduct.

Federal register·2026
Same journal

Findings of Research Misconduct.

Federal register·2025
Same journal

Findings of Research Misconduct.

Federal register·2025
Same journal

Findings of Research Misconduct.

Federal register·2024

Related Experiment Video

Updated: Jun 16, 2026

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode
03:49

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

Published on: October 11, 2024

Copayments for medications. Interim final rule.

    Federal Register
    |February 23, 2010
    PubMed
    Summary

    The Department of Veterans Affairs (VA) is freezing medication copayments for six months. After this period, copayments will resume increases based on the Medical Consumer Price Index for prescription drugs.

    Area of Science:

    • Health Policy
    • Medical Economics
    • Public Health Regulations

    Background:

    • Current Department of Veterans Affairs (VA) regulations mandate annual increases in medication copayments.
    • Copayment adjustments are tied to the prescription drug component of the Medical Consumer Price Index (CPI).
    • Maximum annual copayment amounts are also subject to increase alongside individual copayments.

    Purpose of the Study:

    • To announce and explain amendments to VA medical regulations regarding medication copayments.
    • To implement a temporary freeze on medication copayment rates.
    • To outline the future adjustment mechanism for copayments post-freeze.

    Main Methods:

    • Regulatory amendment process initiated by the Department of Veterans Affairs.

    Related Experiment Videos

    Last Updated: Jun 16, 2026

    Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode
    03:49

    Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

    Published on: October 11, 2024

  • Analysis of the prescription drug component of the Medical Consumer Price Index (CPI).
  • Implementation of a six-month freeze on existing copayment rates.
  • Main Results:

    • Medication copayments will remain at their current levels for the next six months.
    • Following the freeze, copayments will be adjusted based on changes in the prescription drug CPI.
    • The regulatory framework for copayment adjustments is being modified.

    Conclusions:

    • The temporary freeze aims to provide immediate financial relief or predictability for beneficiaries.
    • Future copayment adjustments will continue to be indexed to the prescription drug CPI.
    • These regulatory changes impact medication cost management for veterans within the VA system.